A Non-interventional Study on Vismodegib for Basal Cell Carcinoma With A Treat-To-Target Regimen In Swedish Patients
Author Affiliation(s)
Citation: Bendsöe N, Paoli J, Söderkvist K, Persson B, Halldin C, Ihrlund L, Wolodarski. A Non-Interventional Study on Vismodegib for Basal Cell Carcinoma in Swedish Patients. Dermatol Pract Concept. 2023;13(2):e2023211. DOI: https://doi.org/10.5826/dpc.1302a211
Accepted: April 9, 2023; Published: April 2023
Copyright: ©2023 Bendsöe et al. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (BY-NC-4.0), https://creativecommons.org/licenses/by-nc/4.0/, which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original authors and source are credited.
Funding: Roche AB sponsored this study. We would like to thank all research nurses who assisted with patient inclusion and follow-up. Medical writing support was provided by Eva Karlsson (Scientific Consulting AB) in the preparation of this paper. Responsibility for opinions, conclusions and interpretation of data lies with the authors.
Competing interests: Linda Ihrlund is employed at Roche AB. The other authors have nothing to declare.
Authorship: All authors have contributed significantly to this publication.
Corresponding author: John Paoli, M.D., Professor; Department of Dermatology and Venereology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Tel: +46730404044 E-mail: john.paoli@gu.se
Abstract
Introduction: Real-life data on vismodegib in advanced basal cell carcinoma (aBCC) are limited. Optimal treatment duration is left to the discretion of the physician.
Objectives: To assess the effectiveness, safety and treatment pattern for vismodegib in aBCC in clinical practice.
Methods: In this multicenter, non-interventional, prospective study, 49 Swedish patients planned for vismodegib treatment were included. The treatment pattern observed was treatment until remission, allowing unlimited discontinuations/pauses.
Results: The majority of patients (93.8%), discontinued at least once during the study. Compared to earlier studies there was a decrease of more than 2 months with actual drug intake, reducing the patients burden and costs, at the same time as a high number of responses were seen (87.8%). Median progression-free-survival was 16.7 months, and 90% of the patients were alive at 13.3 months. Ten patients were re-challenged with vismodegib at recurrence or progression, resulting in five partial remissions and three complete remissions.
Conclusions: Clinical response rates with vismodegib for aBCC were similar to those of similar trials despite a shorter and more intermittent treatment duration. The majority of re-challenges lead to partial or complete remissions.
Keywords : Non-interventional, prospective, effectiveness, safety, cohort-study
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
